From: PICALM exerts a role in promoting CRC progression through ERK/MAPK signaling pathway
Features | No. of patients | PICALM expression | p value | |
---|---|---|---|---|
Low | High | |||
All patients | 76 | 44 | 32 | Â |
Age (years) | Â | Â | Â | 0.112 |
 < 65 | 34 | 16 | 18 |  |
 ≥ 65 | 38 | 25 | 13 |  |
Gender | Â | Â | Â | 0.903 |
Male | 41 | 24 | 17 | Â |
Female | 35 | 20 | 15 | Â |
Tumor size | Â | Â | Â | 0.330 |
 < 5 | 36 | 23 | 13 |  |
 ≥ 5 | 38 | 20 | 18 |  |
Grade | Â | Â | Â | 0.222 |
 2 | 66 | 40 | 26 |  |
 3 | 10 | 4 | 6 |  |
Stage | Â | Â | Â | 0.013 |
 1 | 7 | 7 | 0 |  |
 2 | 38 | 23 | 15 |  |
 3 | 27 | 13 | 14 |  |
 4 | 4 | 1 | 3 |  |
T Infiltrate | Â | Â | Â | 0.508 |
 T1 | 1 | 1 | 0 |  |
 T2 | 6 | 6 | 0 |  |
 T3 | 46 | 23 | 23 |  |
 T4 | 23 | 14 | 9 |  |
Lymphatic metastasis (N) |  |  |  | 0.042 |
 N0 | 45 | 30 | 15 |  |
 N1 | 17 | 9 | 8 |  |
 N2 | 14 | 5 | 9 |  |
Metastasis | Â | Â | Â | 0.174 |
 M0 | 72 | 43 | 29 |  |
 M1 | 4 | 1 | 3 |  |